The predictive and prognostic significance of cell‐free DNA concentration in melanoma von Váraljai, R., Elouali, S., Lueong, S.S., Wistuba‐Hamprecht, K., Seremet, T., Siveke, J.T., Becker, J.C., Sucker, A., Paschen, A., Horn, P.A., Neyns, B., Weide, B., Schadendorf, D., Roesch, A.

Volltext

MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies von Hessmann, E, Schneider, G, Ellenrieder, V, Siveke, J T

Volltext

477 pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial von Boeck, S, Ormanns, S, Laubender, R.P, Jung, A, Siveke, J.T, Haas, M, Kirchner, T, Heinemann, V

Volltext

Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting von Real, F.X., Siveke, J.T.

Volltext

Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling von Siebermair, J., Köhler, M.I., Kupusovic, J., Nekolla, S.G., Kessler, L., Ferdinandus, J., Guberina, N., Stuschke, M., Grafe, H., Siveke, J.T., Kochhäuser, S., Fendler, W.P., Totzeck, M., Wakili, R., Umutlu, L., Schlosser, T., Rassaf, T., Rischpler, C.

Volltext

1525P Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreat... von Siveke, J.T., Sinn, M., Dorman, K., Siegler, G.M., Seufferlein, T., Trojan, J., Waldschmidt, D.T., Koenig, A.O., Schipp, D., Liffers, S-T., Kunzmann, V.

Volltext

44P Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial von Ponz-Sarvise, M., Gromke, T., Magdalena, A. Landa, Richly, H., Liffers, S-T., Kasper-Virchow, S., Garonce-Hediger, R., Alvarez, E. Castanon, Paredes, L. Ceniceros, Ortega, A. Chopitea, Siveke, J.T.

Volltext

386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients... von Lahusen, A., Lutz, M.P., Karthaus, M., Kirchner, M., Cheung, P.F., Wisser, S., Ansorge, N., Barmashenko, G., Hoefling, S., Leidig, T., Schulte, M., Waldschmidt, D.T., Budczies, J., Siveke, J.T., Tannapfel, A., Stenzinger, A., Ettrich, T.J., Eiseler, T., Raeth, S., Seufferlein, T.

Volltext

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers von Jahn, A., Rump, A., Widmann, T.J., Heining, C., Horak, P., Hutter, B., Paramasivam, N., Uhrig, S., Gieldon, L., Drukewitz, S., Kübler, A., Bermudez, M., Hackmann, K., Porrmann, J., Wagner, J., Arlt, M., Franke, M., Fischer, J., Kowalzyk, Z., William, D., Weth, V., Oster, S., Fröhlich, M., Hüllein, J., Valle González, C., Kreutzfeldt, S., Mock, A., Heilig, C.E., Lipka, D.B., Möhrmann, L., Hanf, D., Oleś, M., Teleanu, V., Allgäuer, M., Ruhnke, L., Kutz, O., Knurr, A., Laßmann, A., Endris, V., Neumann, O., Penzel, R., Beck, K., Richter, D., Winter, U., Wolf, S., Pfütze, K., Geörg, C., Meißburger, B., Buchhalter, I., Augustin, M., Aulitzky, W.E., Hohenberger, P., Kroiss, M., Schirmacher, P., Schlenk, R.F., Keilholz, U., Klauschen, F., Folprecht, G., Bauer, S., Siveke, J.T., Brandts, C.H., Kindler, T., Boerries, M., Illert, A.L., von Bubnoff, N., Jost, P.J., Metzeler, K.H., Bitzer, M., Schulze-Osthoff, K., von Kalle, C., Brors, B., Stenzinger, A., Weichert, W., Hübschmann, D., Fröhling, S., Glimm, H., Schröck, E., Klink, B.

Volltext

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of... von Haas, M., Siveke, J.T., Schenk, M., Lerch, M.M., Caca, K., Freiberg-Richter, J., Fischer von Weikersthal, L., Kullmann, F., Reinacher-Schick, A., Fuchs, M., Kanzler, S., Kunzmann, V., Ettrich, T.J., Kruger, S., Westphalen, C.B., Held, S., Heinemann, V., Boeck, S.

Volltext

196P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair de... von Schlenk, R.F., Rübsam, M., Teleanu, M-V., Richter, S., Siveke, J.T., Wagner, S., Kopp, H-G., Kindler, T., Illert, L., Golf, A.H-E., Dorman, K., Schreck, N., Benner, A., Süsse, H., Freitag, A., von Kalle, C., Glimm, H., Hübschmann, D., Fröhling, S., Heilig, C.E.

Volltext

LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RA... von Kasper-Virchow, S., Hofheinz, R.D., Stintzing, S., Dechow, T.N., Ettrich, T.J., Sinn, M., Roderburg, C., Fischer von Weikersthal, L., Graeven, U., Mueller, C., Meiler, J., Stein, A., Modest, D.P., Pauligk, C., Virchow, I., Siveke, J.T., Al-Batran, S-E., Schuler, M.H.H., Goetze, T.O.

Volltext

301P Homologous recombination repair (HRR) deficiency in biliary tract cancers: Clinical implications in subsequent therapy lines and correlation with platinum sensitivity von Mavroeidi, I., Seyed Mohammad, T.W., Webersinke, G., Burghofer, J., Piringer, G., Kasper-Virchow, S., Liffers, S-T., Reichinger, A., Kirchweger, P., Heibl, S., Hamacher, R.W., Petzer, A.L., Schuler, M.H.H., Prager, G., Kersting, D.M., Treckmann, J.W., Schildhaus, H-U., Rumpold, H., Siveke, J.T., Doleschal, B.

Volltext

416P Evolutionary and immune microenvironment dynamics determine response to neoadjuvant treatment of oesophageal adenocarcinoma von Barroux, M., Househam, J., Lakatos, E., Ronel, T., Baker, A-M., Salié, H., Mossner, M., Jansen, M., Caravagna, G., Steiger, K., Slotta-Huspenina, J., Weichert, W., Alberstmeier, M., Chain, B., Friess, H., Bengsch, B., Schmid, R., Siveke, J.T., Quante, M., Graham, T.

Volltext

1497P Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities von Hamacher, R.W., Pabst, K.M., Kessler, L., Costa, P.F., Ferdinandus, J., Weber, M., Lippert, M., Lueckerath, K., Hirmas, N., Kostbade, K., Mavroeidi, I.A., Schuler, M.H.H., Ahrens, M., Rischpler, C., Bauer, S., Herrmann, K., Siveke, J.T., Fendler, W.P.

Volltext

487P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair de... von Heilig, C.E., Teleanu, M-V., Bhatti, I.A., Richter, S., Siveke, J.T., Wagner, S., Kopp, H-G., Kindler, T., Illert, L., Golf, A., Dormann, K., Benner, A., Süsse, H., Freitag, A., Von Kalle, C., Glimm, H., Hübschmann, D., Fröhling, S., Schlenk, R.F.

Volltext

Palliative und supportive Therapie des Ösophaguskarzinoms von Lorenzen, S, Siveke, J.T, van Oorschot, B

Volltext

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II tr... von Hartlapp, I., Valta-Seufzer, D., Siveke, J.T., Algül, H., Goekkurt, E., Siegler, G., Martens, U.M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T.J., Held, S., Keller, R., Anger, F., Germer, C.T., Stang, A., Kimmel, B., Heinemann, V., Kunzmann, V.

Volltext

Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity von Mavroeidi, I.-A., Burghofer, J., Kalbourtzis, S., Taghizadeh, H., Webersinke, G., Piringer, G., Kasper, S., Schreil, G., Liffers, S.T., Reichinger, A., Kirchweger, P., Heibl, S., Hamacher, R., Schmitt, C.A., Schuler, M., Prager, G.W., Kersting, D., Treckmann, J., Schildhaus, H.-U., Rumpold, H., Siveke, J.T., Doleschal, B.

Volltext

265 Rac1 is a therapeutic target for pancreatic cancer prevention and treatment von Lubeseder-Martellato, C, Heid, I, Sipos, B, Rieder, S, Schmid, R.M, Siveke, J.T

Volltext